About Nathalie Riebel
Over 30 years in oncology clinical trials
I’m an independent, hands-on clinical operations leader who’s run every kind of oncology trial, from first-in-human dose escalation through global phase 3, including investigator-initiated and master protocols. Founders bring me in when they have a promising asset and need an operator to take it into the clinic
13+
years in Pharma
GW • GSK • Eli Lilly
CRA at G and GW, led clinical operations teams at GSK, and led the oncology franchise inspection readiness program/team at Eli Lilly.
15+
years in CRO Leadership
IQVIA • ICON
Led project management, portfolio and program delivery, and full trial teams as a Director across mid-size and small Oncology Biotechs.
7+
years in Biotech Leadership
ImClone • Delcath • PDS Biotech
Built clinical operations from the ground up: the departments, standards, systems, and teams early-stage biotechs don't have yet.
Three decades across pharma, CRO, and biotech. Here's what it does for you.
If you're a founder with a promising molecule in preclinical and no in-house clinical operations, this is where I come in. I design and operationalize your first-in-human trial, then run it from IND filing through first patient dosed, topline results, and into your next phase of development.
Operational protocol design
CRO selection and oversight
Phase 1 and phase 2 trial setup and execution
Fit-for-purpose vendor oversight, right-sized to your trial, not a bloated system
Study conduct through database lock and topline readout
Inspection readiness and next-phase planning
I'm not an MD guessing at operations. I'm the operator, from IND filing to topline results and beyond.
Experience across 18+ Indications
Tumor Types
-
Experience in:
Breast cancer
Ocular Melanoma
Cholangiocarcinoma
Colorectal
Small Cell Lung Cancer
Melanoma
Head and Neck Cancer
Pancreatic and Renal Cancer
-
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
-
Infantile Hemangioma
Treatment Modalities
-
Monoclonal Antibodies
Immuno-modulator
Interferons
Interleukins
Immune Checkpoints
Oncolytics
-
-
T cell activating platforms
-
Tyrosine kinase
RAF
VEGF
Publications
-
ASCO 2023 Price KAR, Kaczmar JM, Worden FP, Wood LV, Schaaf DT, Riebel N, Chaney MF, Weiss J. Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 6012-6012. DOI: 10.1200/JCO.2023.41.16_suppl.6012 Published online May 31, 2023.
-
ASCO 2022 Weiss J, Chintakutlawar AV, Price KAR, Kaczmar JM, Riebel N, Bedu-Addo FK, Chaney MF, Wood LV. PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab I subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 6041-6041. DOI: 10.1200/JCO.2022.40.16_suppl.6041
-
ESMO TAT 2023 Wood L, McCarthy S, Schaaf D, Riebel N, Jones S, Cotty A, Bick J. HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy. ESMO TAT 2023, Paris, France, March 6-8, 2023. Abstract 246.
-
ESMO 2023 Harrington K, Weiss J, Price K, Kaczmar J, Schaaf D, Riebel N, Jones S, Cotty A, McCarthy S, Wood L. Polyfunctional HPV16-specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). ESMO 2023, Madrid, Spain, October 20-24, 2023. Final Publication Number [FPN] 924P. (Note: the submitted assigned abstract # was 6982).
Built to withstand the inspection before it happens.
When Eli Lilly acquired ImClone Systems, I was chosen to lead inspection readiness for Lilly's oncology franchise, a role created specifically for me. Over 4 years, I built the program from the ground up. I assembled a joint team of ImClone and Lilly quality assurance professionals, shepherded ImClone's drugs through global regulatory inspections, and trained the Lilly team leaders who inherited the programs. I led the backroom during inspections, crafted responses to regulatory agencies, and coached site staff on how to respond to inspectors.
27 FDA inspections. No OAI and 1 company VAI
Inspection readiness isn't something you scramble for when the FDA calls. It's built into how a trial runs from day one. That's how I run yours, so when scrutiny comes, your trial is already prepared for it.
25+
people on the largest team led
$70M
portfolio budget managed
17+
trials from setup to execution
You have a molecule in preclinical. Let's get it to first patient dose.
Working alongside your team, I design and operationalize your first-in-human study so it meets its milestones, withstands scrutiny, and stays on timeline.